¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Behavioral Risk Factor Surveillance System"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® risk factor ÇÑ±Û À§ÇèÀÎÀÚ
¼³¸í   
  ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼­ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î Ã¤ÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£­3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£­3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ À־ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£­3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼­ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» Çϸ鼭 ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£­3/SvÀÌ´Ù.
¿µ¹® rheumatoid factor ÇÑ±Û ·ù¸¶Æ¼½º ÀÎÀÚ
¼³¸í   
  IgGÀÇ FcºÎÀ§¿¡ Àִ Ç׿ø°áÁ¤ÀÎÀÚ¿¡ ´ëÇÑ Ç×ü·Î¼­ ÀüÇüÀûÀΠ¶Ç´Â È®½ÇÇÑ ·ù¸¶Æ¼½º°üÀý¿°(rheumatoid arthritis) È¯ÀÚÀÇ 80%¿¡¼­ ¹ß°ßµÈ´Ù. ·ù¸¶Æ¼½º ÀÎÀڴ IgM, IgG, IgAÁß Çϳª°¡ µÉ ¼ö ÀÖÀ¸³ª ÁַΠIgMÀÌ´Ù. ¼Ò¾Æ·ù¸¶Æ¼½º°üÀý¿°(juvenile rheumatoid arthritis: ¼Ò¾Æ±â¿¡ ¹ß»ýÇϴ ·ù¸¶Æ¼½º°üÀý¿°)À» ºñ·ÔÇÑ, ´Ù¸¥ °áÇÕÁ¶Á÷º´À̳ª °¨¿°º´¿¡µµ ³ªÅ¸³¯ ¼ö ÀÖ´Ù
¿µ¹® growth factor ÇÑ±Û ¼ºÀåÀÎÀÚ
¼³¸í   
  ¼¼Æ÷ÀÇ ºÐÈ­ ¹× ¼ºÀå¿¡ °ü¿©Çϴ ´Ü¹éÁú. ¼ºÀåÀÎÀڴ Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ Å¾ÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù.
¿µ¹® hepatic portal system ÇÑ±Û °£¹®¸Æ°è
¼³¸í   
  À§, ÀÛÀºÃ¢ÀÚÀ̳ª Å«Ã¢ÀÚ¿¡¼­ ¿µ¾çºÐÀ» Èí¼öÇϱâ À§ÇÑ ¸ð¼¼Ç÷°üÁ¶Á÷Àº ¸ðµÎ °£À¸·Î ¿¬°áµÈ´Ù. Áï ¼ÒÈ­±â¿¡ Èí¼öÇÑ ¿µ¾çºÐÀÌ °¡µæÇÑ ÇǴ ¸ðµÎ °£À¸·Î ¿¬°áµÇ´Âµ¥ À̰ÍÀ» ¹®¸Æ°è¶ó°í ÇÑ´Ù.
¿µ¹® system ÇÑ±Û °è, °èÅë
¼³¸í   
  ÀÎü¸¦ ±¸¼ºÇϴ °è´Â ´ÙÀ½°ú °°ÀÌ ±¸ºÐµÈ´Ù.
  
  1) ½ÉÀåÇ÷°ü°èÅë(cardiovascular system)
  
  2) È£Èí±â°è(respiratory system)
  
  3) ¼ÒÈ­±â°è(digeshive system)
  
  4) ºñ´¢±â°è(urinary system)
  
  5) »ý½Ä±â°è(genital system)
  
  6) Ç÷¾×°è(hematologic system)
  
  7) ³»ºÐºñ°è(endocrine system)
  
  8) ½Å°æ°è(nervous system)
  
  9) °ñ°Ý°è(skeletal system)
  
  10) ±ÙÀ°°è(muscular system)
  
  11) ÇǺΰè(integumentary system).
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • behavioral risk factor
    ÇൿÀ§Çè¿äÀÎ
  • risk factor
    À§ÇèÀÎÀÚ
  • behavioral genetics
    ÇൿÀ¯ÀüÇÐ
  • behavioral modification
    Çൿ¼öÁ¤
  • behavioral observation audiometry
    Çൿ°üÂûû·Â°Ë»ç
  • behavioral science
    Çൿ°úÇÐ
  • behavioral therapy
    Çൿ¿ä¹ý
  • epidemiological surveillance
    ¿ªÇа¨½Ã
  • immune surveillance
    ¸é¿ª°¨½Ã
  • immunological surveillance
    ¸é¿ª°¨½Ã
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • post-marketing surveillance
    ½ÃÆÇÈĺÎÀÛ¿ë°¨½Ã
  • surveillance
    °¨½Ã, °¨µ¶
  • attributable risk
    ±âÀÎÀ§Çèµµ
  • absolute risk model
    Àý´ëÀ§Çè¸ðÇü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • risk factor
    À§ÇèÀÎÀÚ
  • surveillance
    °¨½Ã
  • behavioral modification
    Çൿ¼öÁ¤
  • behavioral therapy
    Çൿ¿ä¹ý
  • high risk group
    °íÀ§Ç豺
  • low risk group
    ÀúÀ§Ç豺
  • risk
    À§Çè, À§Çèµµ
  • attributable risk
    ±â¿©À§Çèµµ
  • relative risk
    ºñ±³À§Çèµµ
  • surgical risk
    ¼ö¼úÀ§Çèµµ
  • system analysis
    °èÅëºÐ¼®
  • system
    1.°è, °èÅë, ü°è, 2.ÀåÄ¡, 3.Á¦µµ,
  • Bethesta system
    º£Å×½ºÅ¸ºÐ·ù(¹ý)
  • biliary system
    ´ãµµ°è, ¾µ°³°èÅë
  • blood group system
    Ç÷¾×Çü±º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • behavioral risk factor
    ÇൿÀ§Çè¿äÀÎ
  • risk factor
    À§ÇèÀÎÀÚ
  • behavioral observation audiometry
    Çൿ°üÂûû·Â°Ë»ç
  • behavioral epidemic
    ÇൿÀ¯Çà
  • behavioral genetics
    ÇൿÀ¯ÀüÇÐ
  • behavioral modification
    Çൿ¼öÁ¤
  • behavioral therapy
    Çൿ¿ä¹ý
  • postencephalitic behavioral syndrome
    ³ú¿°ÈÄÇൿÁõÈıº
  • surveillance data
    °ü¸®Á¤º¸Á¶»çÀÚ·á
  • epidemiological surveillance
    ¿ªÇа¨½Ã,
  • immune surveillance
    ¸é¿ª°¨½Ã
  • immunological surveillance
    ¸é¿ª°¨½Ã
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • post-marketing surveillance
    ½ÃÆÇÈĺÎÀÛ¿ëÁ¶»ç
  • surveillance
    °¨½Ã
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • postencephalitic behavioral syndrome
    ³ú¿°ÈÄ ÇൿÁõÈıº
  • PMS : post marketing surveillance
    ½ÃÆÇÈÄ ºÎÀÛ¿ëÁ¶»ç.
  • immune surveillance
    ¸é¿ª°¨½Ã
  • immune surveillance
    ¸é¿ª[ÇÐÀû]°¨½Ã±âÀü
  • immunologic surveillance
    ¸é¿ª°¨½Ã(±â±¸).
  • immunological surveillance
    ¸é¿ª°¨½Ã(±â±¸)(ÊÙ˧Ëà˻˴), ¸é¿ªÁ¶»ç.
  • immunological surveillance
    ¸é¿ª°¨½Ã(±â±¸)(¡­ÊøãÊѦϰ), ¸é¿ªÁ¶»ç.
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • post marketing surveillance
    ½ÃÆÇÈÄ ºÎÀÛ¿ëÁ¶»ç
  • T-tubular system =>transverse tubular system
    T-°è, °¡·Î¼Ò°ü °èÅë
  • absolute risk
    Àý´ëÀ§Çè
  • absolute risk model
    Àý´ëÀ§Çè¸ðµ¨
  • acceptable risk
    ¿ëÀÎÀ§Çèµµ, ¼ö¿ëÀ§Çèµµ
  • anesthetic risk
    ¸¶ÃëÀ§Çèµµ.
  • high risk group
    °íÀ§Çèµµ±º(Ë­Ëô̴̬˴).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • coronary risk factor
    °ü(»ó)(µ¿¸Æ)ÁúȯÀ§Çè¿äÀÎ.
  • risk factor
    À§ÇèÀÎÀÚ
  • epidemiological surveillance
    ¿ªÇÐÀû °¨½Ã(ËçÌ°ËøË§Ëà), ¿ªÇÐÀû °ü¸®Á¤º¸Á¶ »ç.
  • immune surveillance
    ¸é¿ª[ÇÐÀû]°¨½Ã±âÀü
  • immune surveillance
    ¸é¿ª°¨½Ã
  • immunologic surveillance
    ¸é¿ª°¨½Ã(±â±¸).
  • immunological surveillance
    ¸é¿ª°¨½Ã(±â±¸)(¡­ÊøãÊѦϰ), ¸é¿ªÁ¶»ç.
  • immunological surveillance
    ¸é¿ª°¨½Ã(±â±¸)(ÊÙ˧Ëà˻˴), ¸é¿ªÁ¶»ç.
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • post marketing surveillance
    ½ÃÆÇÈÄ ºÎÀÛ¿ëÁ¶»ç
  • surveillance
    °ü¸®Á¤º¸Á¶»ç(Ë´ËöËøËÓÌ¡Ë×), °¨½Ã±â±¸(˧Ëà˻˴).
  • surveillance data
    °ü¸®Á¤º¸Á¶»çÀÚ·á
  • audiometry, behavioral observation
    Çൿ°üÂûû·Â°Ë»ç
  • behavioral - cognitive therapy
    Çൿ(ÇàÅÂ)ÀÎÁöÀû Ä¡·á
  • behavioral abnormality =b. disorder
    ÇൿÀÌ»ó(ú¼ÔÑì¶ßÈ)=ÇൿÀå¾Ö
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Fornical system
    ³úȰ°èÅë
    [¿¾ ¿ë¾î] ³ú±Ã°è
  • Glial cell of peripheral nervous system
    ¸»ÃʾƱ³¼¼Æ÷
    [¿¾ ¿ë¾î] ¸»Ãʱ³¼¼Æ÷
  • Osteon [Harversian system]
    »À´ÜÀ§
    [¿¾ ¿ë¾î] °ñ¿ø
  • Genital system
    »ý½Ä°èÅë
    [¿¾ ¿ë¾î] »ý½Ä±â°èÅë
  • Cardiac conducting system
    ½ÉÀåÀüµµ°èÅë
    [¿¾ ¿ë¾î] ½ÉÀåÀÚ±ØÀüµµ°è
  • Conduction system of heart
    ½ÉÀåÀüµµ°èÅë
    [¿¾ ¿ë¾î] ½ÉÀåÀüµµ°è
  • CENTRAL NERVOUS SYSTEM
    ÁßÃ߽Űæ°èÅë
    [¿¾ ¿ë¾î] ÁßÃ߽Űæ°è
  • Glial cell of central nervous system
    ÁßÃ߾Ʊ³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁßÃß±³¼¼Æ÷
  • Renal system
    ÄáÆÏ°èÅë
    [¿¾ ¿ë¾î] ½ÅÀå°èÅë
  • Primitive duct system
    ¿ø½Ã°ü°èÅë
    [¿¾ ¿ë¾î] ¿ø½Ã°ü°èÅë
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Duffy factor
    ´õÇÇÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immune surveillance theory
    ¸é¿ª °¨½Ã ÀÌ·Ð(Øóæ¹ÊøãÊ×âÖå)
  • immunological surveillance theory
    ¸é¿ª °¨½Ã ÀÌ·Ð(Øóæ¹ÊøãÊ×âÖå)
  • ABO blood group (type) system
    ABOÇ÷¾×Çü (úìäûúþ) ½Ã½ºÅÛ
  • absorption optical system
    Èí¼ö(ýåâ¥) ±¤ÇÐ(ÎÃùÊ) ½Ã½ºÅÛ
  • adiabatic system
    ´Ü¿­(Ó¨æð)½Ã½ºÅÛ
  • ATP regeneration system
    ATPÀç»ý(î¢ßæ) ½Ã½ºÅÛ
  • binding protein transport system
    °áÇÕ ´Ü¹éÁú ¼ö¼Û(Ì¿ùêÓ±ÛÜòõâÃáê) ½Ã½ºÅÛ
  • brain barrier system
    ³úÀ庮(Òàî¡Ûú) ½Ã½ºÅÛ
  • cell-free amino acid incorporating system
    ¹«¼¼Æ÷(Ùíá¬øà) ¾Æ¹Ì³ë»ê ÆíÀÔ(øºìý)¾¾½ºÅÛ
  • cell-free system
    ¹«¼¼Æ÷(Ùíá¬øà)½Ã½ºÅÛ
  • charge relay system
    ÀüÇÏ(ï³ùÃ) ¸±·¹ÀÌ ½Ã½ºÅÛ
  • charge transfer relay system
    ÀüÇÏÀ̵¿(ï³ùÃì¹ÔÑ) ¸±·¹ÀÌ ¾¾½ºÅÛ
  • closed circuit system
    Æó¼âȸ·Î(øÍáðüÞÖØ) ½Ã½ºÅÛ
  • closed system
    ´ÝÈù ½Ã½ºÅÛ
  • cyclophorase system
    »çÀÌŬ·ÎÆ÷·¹À̽º ½Ã½ºÅÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • risk factor
    À§Çè¿äÀÎ
  • high risk group
    °íÀ§Çèµµ±º
  • radiation risk
    ¹æ»ç¼±À§ÇØ, ¹æ»ç¼±À§Çè
  • risk
    À§Çè(µµ), À§Ç輺
  • attenuation factor
    °¨¾à¿ä¼Ò, °¨¼è¿äÀÎ
  • conversion factor
    º¯È¯ÀÎÀÚ
  • factor
    ÀÎÀÚ
  • predisposing factor
    ¼ÒÀÎ, Áúº´¼ÒÁú
  • Q factor
    Å¥ÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½º¾çÀÎÀÚ
  • turbo factor
    Åͺ¸ÀÎÀÚ
  • array system
    ¹è¿­ÀåÄ¡, ¹è¿­Ã¼°è
  • cardiovascular system
    ½ÉÀåÇ÷°ü°è
  • central nervous system [=CNS]
    ÁßÃ߽Űæ°è(Åë)
  • CNS [=central nervous system]
    ÁßÃ߽Űæ°è(Åë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CF calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ...
CDC-BRFS Centers for Disease Control Behavioral Risk Factor Survey
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
RF radial fiber; radio frequency; receptive field; regurgitant fraction; Reitland-Franklin [unit]; rela...
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
BRFSS Behavioral Risk Factor Surveillance System
YRBSS Youth Risk Behavior Surveillance System
NEISS National Electronic Injury Surveillance System
NNDSS National Notifiable Disease Surveillance System
NREVSS National Respiratory and Enteric Virus Surveillance System
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • epidemiological surveillance
    ¿ªÇÐÀû °¨½Ã
  • coronary risk factor
    °ü»ó µ¿¸Æ Áúȯ À§Çè ¿äÀÎ
  • risk factor
    À§Çè ¿äÀÎ, À§Çè ¿ä¼Ò, À§Çè ÀÎÀÚ
    °³ÀÎÀ̳ª ´Üü°¡ ÁúȯÀ̳ª Àå¾Ö¿¡ °É¸®±â ½±°Ô ÇÏ´Â ¿øÀÎÀÌ µÇ´Â ¿ä¼Ò·Î¼­ ¹Î°¨ÇÑ »ç¶÷µé¿¡¼­ ¹ß»ý ºóµµ¿Í Á¤µµ¸¦ Áõ°¡½ÃŲ´Ù.
  • behavioral factor
    Çൿ ¿äÀÎ
  • absolute risk
    Àý´ë À§Çè
  • anesthetic risk
    ¸¶Ãë À§Çèµµ
  • benefit/risk ratio
    À¯ÀÍ/À¯ÇØ ºñÀ²
  • explosion risk
    Æø¹ß À§Ç輺
  • high risk group
    °íÀ§Çèµµ±º
  • operative risk
    ¼ö¼ú À§Çèµµ
  • risk
    À§Çè, À§Çèµµ, À§Ç輺
  • risk management
    ¼úÀÚÀÇ ¾ÈÀü ¼öÄ¢
  • risk principle
    À§Çèµµ ¿ø¸®
  • behavioral abnormality
    Çൿ ÀÌ»ó
    µ¿ÀǾî=behavioral disorder.
  • behavioral arousal
    Çൿ °¢¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
risk factor <statistics> A clearly defined occurrence or characteristic that has been associated with the increased rate of a subsequently occurring disease.
(14 Oct 1997)
cancer, colon: screening and surveillance Colon cancer is both preventable and curable. It is preventable by removing precancerous colon polyps. It is curable if early cancer is surgically removed before cancer spread to other parts of the body. Therefore, if screening and surveillance programs were practiced universally, there would be a major reduction in the incidence and mortality of colon cancer.
(12 Dec 1998)
population surveillance <epidemiology> Ongoing scrutiny of a population (general population, study population, target population, etc.), generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than by complete accuracy.
(12 Dec 1998)
post-marketing surveillance Procedure implemented after a drug has been licensed for public use, designed to provide information on use and on occurrence of side effects, adverse effects, etc.
(05 Mar 2000)
product surveillance, postmarketing Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
(12 Dec 1998)
sentinel surveillance Monitoring of rate of occurrence of specific conditions to assess the stability or change in health levels of a population. It is also the study of disease rates in a specific cohort, geographic area, population subgroup, etc. To estimate trends in larger population.
(12 Dec 1998)
surveillance Oversight; watch; inspection; supervision. "That sort of surveillance of which . . . The young have accused the old." (Sir W. Scott)
Origin: F, fr. Surveiller to watch over; sur over + veiller to watch, L. Vigilare. See Sur-, and Vigil.
Source: Websters Dictionary
(01 Mar 1998)
immune surveillance <immunology> The hypothesis that lymphocyte traffic ensures that all or nearly all parts of the vertebrate body are surveyed by visiting lymphocytes in order to detect any altered self material, for example mutant cells.
(18 Nov 1997)
immunological surveillance <immunology> The hypothesis that lymphocyte traffic ensures that all or nearly all parts of the vertebrate body are surveyed by visiting lymphocytes in order to detect any altered self material, for example mutant cells.
(18 Nov 1997)
immunologic surveillance The theory that T-cells monitor cell surfaces and detect structural changes in the plasma membrane and/or surface antigens of virally or neoplastically transformed cells.
(12 Dec 1998)
absolute risk <statistics> The excess risk due to exposure to a specific hazard (disease, injury, etc.)
(15 Jan 1998)
acceptable risk <statistics> This relates to the potential for suffering disease or injury that will be tolerated by an individual, group, or society in exchange for the benefits of using a substance or process that will cause such disease or injury.
Acceptability of risk depends on scientific data, social, economic, and political factors, and on the perceived benefits arising from a chemical or process that creates the risk in question.
(15 Jan 1998)
attributable risk The rate of a disease or other outcome in exposed individuals that can be attributed to the exposure.
(05 Mar 2000)
cardiac risk A term to describe overall risk of developing heart disease (blockage of the coronary arteries). Typical risk factors include: diabetes, high blood pressure, prior heart attack, high cholesterol, obesity, smoking and a family history for heart attacks in parents or siblings.
(27 Sep 1997)
recurrence risk In medical genetics, the recurrence risk is the chance that a genetic (inherited) disease present in the family will recur in that family and affect another person (or persons). It is the chance of lightning striking twice (or thrice, etc.).
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Behavioral Risk Factor Surveillance System - »õâ Telephone surveys are conducted to monitor prevalence of the major behavioral risks among adults associated with premature MORBIDITY and MORTALITY. The data collected is in regard to actual behaviors, rather than on attitudes or knowledge. The Centers for Disease Control and Prevention (CDC) established the Behavioral Risk Factor Surveillance System (BRFSS) in 1984.
    Synonyms : BRFSS, Behavior Risk Factor Surveillance System
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • behavioral
    ÇൿÀÇ;Çൿ¿¡ °üÇÑ
  • surveillance
    °¨½Ã; °¨µ¶
  • electronic surveillance
    ÀüÀÚ °¨½Ã(Á¤º¸ ¼öÁý)
  • immune surveillance
    IMMUNOLOGICAL SURVEILLANCE
  • surveillance
    °¨½Ã;°¨µ¶;under ~ °¨µ¶À» ¹Þ°í
  • risk
    À§Çè
  • run a risk
    ¸ðÇèÇÏ´Ù
  • calculated risk
    ¿¹ÃøµÇ´Â À§Çè(½ÇÆÐ)
  • catastrophe risk
    ºñ»ó ÀçÇØ À§Çè
  • country risk
    ±¹°¡º° À§Çèµµ(ÇØ¿Ü À¶ÀÚ¸¦ ÇØÁÙ ¶§ÀÇ À¯ÀÚ ´ë»ó±¹ÀÇ ½Å¿ëµµ)
  • risk
    À§Çè(¼º);¸ðÇè;À§Çè(·ü);º¸Çè±Ý(¾×);ÇǺ¸ÇèÀÚ(¹°);À§Å·ӰÔÇÏ´Ù;¸ðÇèÇÏ´Ù;(À§ÇèµîÀ»)°¢¿ÀÇϰí ÀÖ´Ù;°¨ÇàÇÏ´Ù;°¨È÷...ÇÏ´Ù
  • risk capital
    =VENTURE CAPITAL
  • risk manager
    º¸Çè ´ã´ç ÀÓÁ÷¿ø
  • risk-benefit ratio
    À§Ç輺°ú ¼öÀͼº°úÀÇ ºñÀ²
  • risk-money
    ºÎÁ·±Ý º¸»ó ¼ö´ç(ÀºÇà µî¿¡¼­ Ãâ³³°è¿ø¿¡°Ô ÁÖ´Â)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á